Netupitant / palonosetron (Akynzeo®) oral capsule is recommended as an option for restricted use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin ­based cancer chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Netupitant / palonosetron (Akynzeo®) oral capsule is not recommended for use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.